Micron Solutions (MICRD) 10-K 19 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 18, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	MICRON SOLUTIONS INC /DE/
Entity Central Index Key	0000819689
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,872,208
Entity Public Float			$ 9,260,225
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Trading Symbol	micr

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,715	$ 606,988
Restricted cash	0	350,000
Trade accounts receivable, net of allowance for doubtful accounts of $40,000 at December 31, 2018 and 2017	2,325,804	2,595,248
Inventories	3,685,059	3,413,199
Assets held for sale, net	688,750	0
Prepaid expenses and other current assets	389,390	460,954
Total current assets	7,090,718	7,426,389
Property, plant and equipment, net	5,131,773	5,744,039
Assets held for sale, net	0	688,750
Intangible assets, net	53,155	55,133
Other assets	5,140	10,289
Total assets	12,280,786	13,924,600
Current liabilities:
Revolving line of credit	2,025,592	1,879,047
Term notes payable, current portion	389,420	367,779
Subordinated promissory notes, current portion	0	350,000
Accounts payable	1,200,298	1,534,349
Accrued expenses and other current liabilities	459,108	320,065
Contract liabilities, current portion	560,802	426,457
Total current liabilities	4,635,220	4,877,697
Long-term liabilities:
Term notes payable, non-current portion	3,557,458	3,978,415
Total long-term liabilities	3,557,458	3,978,415
Total liabilities	8,192,678	8,856,112
Commitments and Contingencies
Shareholders' equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued	0	0
Common stock, $0.01 par value; 10,000,000 shares authorized; 3,926,491 issued, 2,861,008 outstanding at December 31, 2018 and 3,926,491 issued, 2,839,274 outstanding at December 31, 2017	39,265	39,265
Additional paid-in-capital	11,604,817	11,532,207
Treasury stock at cost, 1,065,483 shares at December 31, 2018 and 1,087,217 shares at December 31, 2017	(2,907,490)	(2,966,798)
Accumulated deficit	(4,648,484)	(3,536,186)
Total shareholders’ equity	4,088,108	5,068,488
Total liabilities and shareholders’ equity	$ 12,280,786	$ 13,924,600

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Consolidated Balance Sheets [Abstract]
Allowance for doubtful accounts receivable, current	$ 40,000	$ 40,000
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	3,926,491	3,926,491
Common stock, shares outstanding	2,861,008	2,839,274
Treasury stock, shares	1,065,483	1,087,217

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Consolidated Statements of Operations [Abstract]
Net sales	$ 19,564,981	$ 20,102,662
Cost of sales	17,241,289	17,810,284
Gross profit	2,323,692	2,292,378
Selling and marketing	730,863	841,845
General and administrative	2,243,595	2,357,909
Research and development	106,814	111,014
Total operating expenses	3,081,272	3,310,768
Net income (loss) from operations	(757,580)	(1,018,390)
Other income (expense):
Interest expense	(391,437)	(395,085)
Other income, net	52,878	57,419
Total other expense, net	(338,559)	(337,666)
Net loss before income tax provision (benefit)	(1,096,139)	(1,356,056)
Income tax provision (benefit)	2,168	(960)
Net loss	$ (1,098,307)	$ (1,355,096)
Earnings (loss) per share - basic and diluted	$ (0.39)	$ (0.48)
Weighted average common shares outstanding - basic and diluted	2,850,397	2,824,061

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2016	$ 39,265	$ 11,457,320	$ (3,028,564)	$ (2,181,090)	$ 6,286,931
Shares, Outstanding, Beginning Balance at Dec. 31, 2016	3,926,491		1,109,852
Share-based compensation - options		48,129			$ 48,129
Issuance of common stock from treasury, shares			(22,635)		0
Issuance of common stock from treasury		26,758	$ 61,766		$ 88,524
Net loss				(1,355,096)	(1,355,096)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2017	$ 39,265	11,532,207	$ (2,966,798)	(3,536,186)	5,068,488
Shares, Outstanding, Ending Balance at Dec. 31, 2017	3,926,491		1,087,217
Share-based compensation - options		56,168			$ 56,168
Issuance of common stock from treasury, shares			(21,734)		0
Issuance of common stock from treasury		16,442	$ 59,308		$ 75,750
Net loss				(1,098,307)	(1,098,307)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2018	$ 39,265	$ 11,604,817	$ (2,907,490)	(4,648,484)	4,088,108
Shares, Outstanding, Ending Balance at Dec. 31, 2018	3,926,491		1,065,483
Change in accounting principle (see Note 3)				$ (13,991)	$ (13,991)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (1,098,307)	$ (1,355,096)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Gain on sale of property, plant and equipment	(8,360)	(21,750)
Depreciation and amortization	1,504,037	1,611,139
Impairment of intangibles	0	1,771
Non-cash interest expense	62,120	63,846
Change in allowance for doubtful accounts	0	10,000
Share-based compensation expense	131,918	136,653
Changes in operating assets and liabilities:
Accounts receivable	269,444	(328,640)
Inventories	(348,121)	(353,114)
Prepaid expenses and other current assets	43,394	153,408
Other non-current assets	995	145,942
Accounts payable	(343,038)	(209,912)
Accrued expenses and other current liabilities	157,376	(13,296)
Contract liabilities	134,345	79,179
Other non-current liabilities	0	(156,953)
Net cash provided by (used in) operating activities	505,803	(236,823)
Cash flows from investing activities:
Purchases of property, plant and equipment	(801,884)	(924,621)
Proceeds from sale of property, plant and equipment	8,360	34,600
Cash paid for patents and trademarks	(2,661)	(29,307)
Net cash provided by (used in) investing activities	(796,185)	(919,328)
Cash flows from financing activities:
Proceeds from (payments on) revolving line of credit, net	146,545	93,252
Proceeds from term notes payable	0	4,500,000
Payments on term notes payable	(419,047)	(2,606,688)
Payments of debt issuance costs	(42,389)	(153,806)
Payment on subordinated debt	(350,000)	(100,000)	$ (50,000)
Net cash provided by (used in) financing activities	(664,891)	1,732,758
Net change in cash and cash equivalents and restricted cash	(955,273)	576,607
Cash and cash equivalents and restricted cash, beginning of period	956,988	380,381
Cash and cash equivalents and restricted cash, end of period	1,715	956,988	$ 380,381
Supplemental Cash Flow Information
Cash paid for interest	313,425	324,641
Non-cash activities:
Issuance of treasury stock for directors fees	75,750	$ 88,524
Adjustment to accumulated deficit for change in accounting principle (Note 3)	$ (13,991)

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2018
Description of Business [Abstract]
Description of Business	1. De scription of Business  Micron Solutions ® , Inc., a Delaware corporation ("Micron Solutions"), through its wholly-owned Massachusetts operating subsidiary, Micron Products ® , Inc. (“Micron” and together with Micron Solutions, the "Company"), is a diversified contract manufacturing organization (“CMO”) that produces highly-engineered, innovative components requiring precision machining and thermoplastic injection molding. The Company also manufactures components, devices and equipment for military, law enforcement, automotive and consumer products applications. The Company's capabilities include the production and sale of silver/silver chloride coated and conductive resin sensors used as consumable component parts in the manufacture of integrated disposable electrophysiological sensors. The Company’s machining operations produce quick-turn, high volume and patient-specific orthopedic implant components and instruments. The Company also has custom thermoplastic injection molding capabilities as well as a full array of design, engineering, production services and management. The Company competes globally, with approximately 45% of its revenue derived from exports.  Today, the Company has diversified manufacturing capabilities with the capacity to participate in full product life-cycle activities from early stage development and engineering and prototyping to full scale manufacturing as well as packaging and product fulfillment services.  Liquidity and Management’s Plan  At December 31, 2018, the Company identified certain conditions and events which in the aggregate required management to perform an assessment of the Company’s ability to continue as a going concern. These conditions included the Company’s negative financial history and the Company’s ability to generate sufficient cash to support the Company’s operations and to meet debt service requirements under the Company’s credit agreement. As of December 31, 2018, the Company has $1,715 of cash and approximately $285,000 of borrowing capacity on its revolving line of credit. As a result of the above factors, management has performed an analysis to evaluate the entity’s ability to continue as a going concern for one year after the financial statements issuance date.  Management’s analysis includes forecasting future revenues, expenditures and cash flows, taking into consideration past performance and the requirements under the credit agreement. Revenue and cash flow forecasts are dependent on the Company’s ability to fill booked orders from existing customers, its ability close new and expanded business and to improve overall financial performance.  Management also believes that it is probable that the Company will close on the sale of the vacant buildings, shown as assets held for sale on the consolidated balance sheets, on or about June 30, 2019 and the proceeds of approximately $700,000 will be applied against the Company’s revolver. Additionally, subsequent to year end, on March 7, 2019, the Company entered into the First Amendment to the Credit and Security Agreement in which the quarterly debt service coverage ratio mea surement requirements for 2019 were amended to lessen the burden of compliance. See Note 7.  Based on management’s analysis, t he Company believes that cash flows from its operations, together with its existing working capital, booked orders, the sale of the vacant buildings, expense management, and its Revolver, will be sufficient to fund operations at current levels and repay debt obligations over the next twelve months from the financial statements issuance date; however, there can be no assurance that the Company will be able to do so.

Accounting Policies

Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Accounting Polices	2. Accounting Policies  Principles of consolidation  The consolidated financial statements (the "financial statements") include the accounts of Micron Solutions, Inc. and its operating subsidiary, Micron Products, Inc. All intercompany balances and transactions have been eliminated in consolidation.  Use of estimates  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.  Revenue recognition  The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ ASU”) No. 2014-09, “Revenue from Contracts with Customers, Topic 606” (“Topic 606”) effective January 1, 2018 using the modified retrospective approach. Under the modified retrospective method, a cumulative effect of initially applying the new standard is recorded as an adjustment to the opening balance of retained earnings at the date of initial application. By electing to use this method, there is no restatement of the comparative periods presented. As permitted by Topic 606 transition guidance, the Company applied the new standard only to contracts that were not completed contracts at the date of initial application, and therefore, the Company only evaluated those contracts that were in-process and not completed before January 1, 2018.  Beginning January 1, 2018, the Company applied Topic 606 using the five step approach outlined in the guidance: (1) Identify contracts with the customer, (2) Identify the performance obligations in the contract, (3) Determine the transaction price, (4) Allocate the transaction price to the performance obligations in the contract, and (5) Recognize revenue when (or as) the entity satisfies the performance obligations.  The Company determined that customer purchase orders represent contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. Shipping and handling activities for which the Company is responsible are not a separate promised service but instead are activities to fulfill the entity’s promise to transfer goods and are recognized at the same time as the related performance obligation is satisfied.  The Company determines the transaction price as the amount of consideration it expects to receive in exchange for transferring promised goods or services to the customer. If a contract includes a variable amount, such as a rebate, then the Company estimates the transaction price using either the expected value or the most likely amount of consideration to be received, depending upon the specific facts and circumstances. The Company includes estimated variable consideration in the transaction price only to the extent it is probable that a significant reversal of revenue will not occur when the uncertainty is resolved. The Company updates its estimate of variable consideration at the end of each reporting period to reflect changes in facts and circumstances.  The Company recognizes revenue at the point in time when it transfers control of the promised goods or services to the customer, which typically occurs once the product has shipped or has been delivered to the customer. For certain customer warehousing agreements, delivery is deemed to have occurred when the customer pulls inventory out of the warehouse for use in their production. Additionally, for certain customers, delivery is deemed to have occurred when items are delivered to bill and hold locations at the Company’s facility.  The Company evaluated the nature of any guarantees or warranties related to its contracts with customers. The Company determined that any such warranty is an assurance-type warranty that only covers the products’ compliance with agreed-upon specifications and does not provide the customer with a service in addition to the assurance that the product complies with agreed-upon specifications.  Certain contracts contain prepayment terms that result in liabilities for customer deposits. Additionally, certain contracts provide for invoicing before all performance obligations have been fulfilled which results in deferred revenue. Customer deposits and advance invoicing are recorded as contract liabilities on the consolidated balance sheet.  The Company generally expenses sales commission when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.  The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected duration of one year or less.  Fair value of financial instruments  The carrying amount reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the immediate or short-term nature of such instruments. The carrying value of debt approximates fair value since it provides for market terms and interest rates.  Concentration of credit risk  Financial instruments which potentially expose the Company to concentrations of credit risk consist primarily of accounts receivable and cash and cash equivalents. It is the Company’s policy to place its cash in high quality financial institutions. The Company does not believe significant credit risk exists above federally insured limits with respect to these institutions.  Accounts receivable are customer obligations due under normal trade terms. A large portion of the Company's products are sold to large diversified medical, military and law enforcement product manufacturers. The Company does not generally require collateral for its sales; however, the Company believes that its terms of sale provide adequate protection against credit risk.  During the year ended December 31, 2018 , the Company had net sales to three customers constituting 18% , 12% and 10% of total net sales. Accounts receivable from these three customers at December 31, 2018 was 19% , 7% and 7% , respectively, of the total accounts receivable balance at year end. During the year ended December 31, 2017 , the Company had net sales to two customers constituting 17% and 10% , respectively, of total net sales. Accounts receivable from these two customers at December 31, 2017 was 13% and 3% , respectively, of the total accounts receivable balance at year end.  During the years ended December 31, 2018 and 2017 approximately 75% of the Company’s net sales were to customers in the medical industry. The Company also had net sales to customers in the automotive, industrial, consumer products, and military and law enforcement industries.  The Company competes globally, with approximately 45% of its revenue derived from exports. While some risks exist in foreign markets, the Company’s customers have historically been based in stable regions. To reduce the risks associated with foreign shipments and currency exchange fluctuations, the title to most of the products are transferred to the customers when shipped and payment is required in U.S. Dollars. The Company also has agreements with certain foreign customers to hold inventory at customer locations where title transfers and revenue is recognized when the product is consumed by the customer. To further reduce risk, the Company sells to certain markets only with cash-in-advance or letter-of-credit terms. In addition, accounts receivable insurance is used where available and appropriate to further reduce risk in these markets.  Cash and cash equivalents  Cash and cash equivalents consist of cash on hand and on deposit in high quality financial institutions with maturities of three months or less at the time of purchase. The Company’s credit agreement provides for a daily sweep of cash balances against the balance of the Revolver (see Note 7).  Restricted cash  Restricted cash represents cash obtained pursuant to the Company's credit agreement for the designated purpose of discharging the subordinated promissory notes, which occurred on January 2, 2018 (see Note 7).  Accounts receivable and allowance for doubtful accounts  Accounts receivable represent amounts invoiced by the Company. Management maintains an allowance for doubtful accounts based on information obtained regarding individual accounts and historical experience. Amounts deemed uncollectible are written off against the allowance for doubtful accounts. The Company insures receivables for certain customers based upon several factors. Such factors include the customer’s payment terms, ordering patterns and volume requirements, the customer’s payment history, or general economic conditions of the region in which a customer is located.  Inventories  The Company values its inventory at the lower of average cost, or net realizable value, and cost is determined using first in first out (FIFO) or average cost. The Company reviews its inventory for quantities in excess of production requirements, obsolescence and for compliance with internal quality specifications. A review of inventory on hand is made at least annually and obsolete inventory may be disposed of and/or recycled. Any adjustments to inventory would be equal to the difference between the cost of inventory and the estimated net market value based upon assumptions about future demand, market conditions and expected cost to distribute those products to market. The Company also has supply agreements with certain foreign customers to hold inventory at the customer’s warehouses.  Property, plant and equipment  Property, plant and equipment are recorded at cost and include expenditures which substantially extend their useful lives. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs are charged to earnings as incurred. When equipment is retired or sold, the resulting gain or loss is reflected in earnings.  Assets held for sale  Property classified as held for sale is measured at the lower of its carrying value or fair value less cost to sell. Gains or losses are recognized for any subsequent changes to fair value less cost to sell; however, gains that may be recognized are limited by cumulative losses previously recognized. Property held for sale is not depreciated.  Fair value hierarchy  The Company groups its assets and liabilities measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.  Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities. Valuations are obtained from readily available pricing sources.  Level 2 – Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using unobservable inputs to pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.  In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.  At December 31, 2018 and 2017, assets held for sale is the only item in the financial statements reflected at fair value. Assets held for sale are considered level 3. The fair value of assets held for sale was determined using the sales price per the amended purchase and sale agreement, less the estimated cost to sell (see Note 6).  Long-lived and intangible assets  The Company assesses the impairment of long-lived assets and intangible assets with finite lives annually or whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. Based upon the annual review, the Company did not record any impairment charges in 2018. The Company recorded impairment charges of $1,771 in 2017.  Intangible assets consist of the following:      Estimated December 31, 2018 December 31, 2017  Useful Life Accumulated Accumulated  (in years) Gross Amortization Net Gross Amortization Net  Patents and trademarks 10 $ 36,880 $ 12,134 $ 24,746 $ 22,911 $ 9,888 $ 13,023  Patents and trademarks pending — 2,143 — 2,143 13,786 — 13,786  Trade names 15 29,398 3,132 26,266 29,062 738 28,324  Total intangible assets $ 68,421 $ 15,266 $ 53,155 $ 65,759 $ 10,626 $ 55,133  Amortization expense related to intangible assets, excluding the 2017 impairment charge noted above, was $4,639 and $2,496 in 2018 and 2017 , respectively. Estimated future annual amortization expense for currently amortizing intangible assets is expected to approximate $4,000 through 2031.  Income taxes  The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates in effect for the year in which the differences are expected to reverse.  The Company follows the provisions of FASB ASC 740, “Accounting for Income Taxes”, which provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized. No interest and penalties related to uncertain tax positions were incurred during 2018 and 2017. The Company’s primary operations are located in the United States. Tax years ended December 31, 2015 or later remain subject to examination by the IRS and state taxing authorities.  Share-based compensation  Share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the share-based grant).  Earnings per share data  Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares.  Research and development  Research and development expenses include costs directly attributable to conducting research and development programs primarily related to the development of a unique process to improve silver coating during the manufacturing processes, including the design and testing of specific process improvements for certain medical device components. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, and services provided by outside contractors. All costs associated with research and development programs are expensed as incurred.  Recently issued accounting pronouncements  In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Based upon this review, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s consolidated financial statements.  In February 2016 the FASB issued ASU No. 2016-02, Leases, which requires a lessee to recognize lease liabilities for the lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and right-of-use assets, representing the lessee’s right to use, or control the use of, specified assets for the lease term. The ASU became effective on January 1, 2019. As of the date of this report, the Company is the lessee of office equipment in a single operating lease and is the lessee of a parking lot. The Company is not a lessor in any arrangements. The Company does not expect any material impact on reporting or on the results of operations.  Reclassification of prior period balances  Amounts in prior year financial statements are reclassified when necessary to conform to the current year presentation.

Change in Accounting Principle

Change in Accounting Principle	12 Months Ended
	Dec. 31, 2018
Change in Accounting Principle [Abstract]
Change In Accounting Principle	 3. Change in Accounting Principle  Revenue Recognition  Based on the Company’s assessment, the implementation of Topic 606 affects the timing of certain revenue related transactions primarily resulting from the earlier recognition of the Company's tooling revenue and costs. Under legacy GAAP, the Company accounted for tooling as multiple element arrangements whereby revenue and cost were recognized over a period of time after the tool was completed. Upon adoption of ASU 2014-09, tooling sales and costs are now recognized at the point in time upon which the tool is complete and the Company has satisfied all its performance obligations under the contract.  As a result of the initial application of Topic 606, the Company made an adjustment to its beginning accumulated deficit of ( $13,991 ) to recognize the remaining deferred revenue ( $18,333 ) and deferred costs ( $32,324 ) recorded as of December 31, 2017 relative to certain completed tooling sales.  The table below compares the affected lines on the consolidated statements of operations as presented to legacy GAAP treatment.      Year Ended  December 31,  2018 2018  As presented Legacy GAAP  Net sales $ 19,564,981 $ 19,208,155  Cost of sales 17,241,289 16,979,892  Gross profit 2,323,692 2,228,263   Net loss from operations (757,580) (853,009)  Net loss before income tax provision (benefit) (1,096,139) (1,191,568)  Net loss $ (1,098,307) $ (1,193,736)  Earnings (loss) per share - basic and diluted $ (0.39) $ (0.42)  Weighted average common shares outstanding - basic and diluted 2,850,397 2,850,397   The table below compares the affected lines on the consolidated balance sheets as presented to legacy GAAP treatment.      December 31, December 31,  2018 2018  As presented Legacy GAAP  Assets  Current assets:  Prepaid expenses and other current assets $ 389,390 $ 488,817  Total current assets 7,090,718 7,190,145  Other assets 5,140 167,110  Total assets $ 12,280,786 $ 12,542,183  Liabilities and Shareholders’ Equity  Current liabilities:  Contract liabilities, current portion $ 560,802 $ 697,733  Total current liabilities 4,635,220 4,772,151  Long-term liabilities:  Contract liabilities, non-current portion — 219,895  Total long-term liabilities 3,557,458 3,777,353  Total liabilities 8,192,678 8,549,504  Shareholders’ equity :  Accumulated deficit (4,648,484) (4,743,913)  Total shareholders’ equity 4,088,108 3,992,679  Total liabilities and shareholders’ equity $ 12,280,786 $ 12,542,183  Contract liabilities would be presented as customer deposits and deferred revenue under legacy GAAP.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2018
Inventories [Abstract]
Inventories	4. Inventories  Inventories consist of the following:      December 31, December 31,  2018 2017  Raw materials $ 1,079,887 $ 1,100,187  Work-in-process 1,105,272 822,244  Finished goods 1,499,900 1,490,768  Total $ 3,685,059 $ 3,413,199  The total cost of silver in our inventory as raw materials, as work-in-process or as a plated surface on finished goods had an estimated cost of $461,272 and $536,963 at December 31, 2018 and 2017 , respectively.

Property, Plant and Equipment,

Property, Plant and Equipment, net	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net	5. Property, Plant and Equipment, Net  Property, plant and equipment, net consist of the following:      Asset Lives December 31, December 31,  (in years) 2018 2017  Machinery and equipment 3 to 15 $ 17,978,781 $ 17,498,586  Building and improvements 5 to 25 3,991,951 3,986,715  Vehicles 3 to 5 98,119 90,713  Furniture, fixtures, computers and software 3 to 5 1,440,071 1,542,027  Construction in progress 168,094 17,412  Total property, plant and equipment 23,677,016 23,135,453  Less: accumulated depreciation (18,545,243) (17,391,414)  Property, plant and equipment, net $ 5,131,773 $ 5,744,039  For the year ended December 31, 2018 , the Company recorded $1,499,398 of depreciation expense compared to $1,608,643 for the year ended December 31, 2017 . There are no commitments related to the completion of construction in process as of December 31, 2018 .

Assets Held For Sale

Assets Held For Sale	12 Months Ended
	Dec. 31, 2018
Assets Held For Sale [Abstract]
Assets Held For Sale	6. Assets Held for Sale  In January 2016, the Company entered into a Purchase and Sale Agreement with a Buyer (collectively the “Parties”) to sell two unoccupied buildings, with a total of approximately 52,000 square feet, and land, at its Fitchburg, Massachusetts campus. As a result, the Company has since classified the property as Assets Held for Sale. The carrying value of $665,000 approximates the fair value less the expected cost to sell.  The Parties have since entered into multiple amendments which provided for, among other things, an extension of the expiration date of the agreement to June 2019 in exchange for monthly extension fees. The closing is expected to take place by the end of June 2019. 

Debt

Debt	12 Months Ended
	Dec. 31, 2018
Debt [Abstract]
Debt	7. Debt  The following table sets forth the items which comprise debt for the Company:      December 31, December 31,  2018 2017  Revolving line of credit $ 2,025,592 $ 1,879,047  Subordinated promissory notes $ — $ 350,000   Total term notes payable, net of issuance costs $ 3,946,878 $ 4,346,194  Less current portion, net 389,420 367,779  Term notes payable, non-current, net 3,557,458 3,978,415   Total short and long term debt, net $ 5,972,470 $ 6,575,241  Bank Debt  On December 29, 2017, the Company entered into a three -year $9,500,000 Credit and Security Agreement (the “credit agreement”) with a Massachusetts trust company, replacing the credit facility and forbearance agreement with the Company’s previous lender. The credit agreement also provided funds with which to discharge the subordinated promissory notes.  The credit agreement includes a revolving line of credit of up to $5.0 million (“Revolver”), a machinery and equipment term loan of $2.5 million (“Equipment Loan”) and a real estate term loan of $2.0 million (“Real Estate Loan” and together with the “Equipment Loan” the “Term Loans”).  Revolver  The Revolver allows for interest only payments during the term of the facility with the full principal outstanding balance to be paid upon maturity on December 29, 2020 . Interest on all borrowings from the Revolver shall be equal to the Wall Street Journal prime rate (“Prime Rate”) plus 0.5%. In lieu of having interest charged at the Prime Rate, the Company shall have the option, on the last day of each month, (the “LIBOR Option”) to have interest charged at a rate of interest equal to the daily one-month LIBOR plus 3.25% for the following month. The interest rate will automatically convert back to the Prime Rate at the beginning of the next month unless the Company elects the LIBOR Option for the next month. The interest rate at December 31, 2018 was 5.59% .  This Revolver carries a provision for a quarterly unused facility fee equal to 0.25% per annum of the average daily undisbursed face amount of the Revolver during the three months immediately preceding the applicable due date and has no prepayment penalty. The credit agreement provides for a daily sweep of cash balances against the balance of the Revolver. Availability to borrow under the Revolver is based on conditions defined in the credit agreement and amounts to $ 284,968 at December 31, 2018.  Term Loans  The Equipment Loan requires monthly principal payments of approximately $29,762 , payable on the first day of each month commencing February 1, 2018. The Equipment Loan is based upon an 84 month amortization with a balloon payment of approximately $1,458,333 due and payable in full upon maturity on December 29, 2020 .  The Real Estate Loan requires monthly principal payments of approximately $8,333 , payable on the first day of each month commencing February 1, 2018. The Real Estate Loan is based upon a 240 month amortization with a balloon payment of approximately $1,708,333 due and payable in full upon maturity on December 29, 2020 .  Interest on the Term Loans shall be at such Wall Street Journal prime rate plus 0.75%. In lieu of having interest charged at the Prime Rate, the Company shall have a LIBOR Option, as described above, to have interest charged at a rate of interest equal to the daily one-month LIBOR plus 3.5% for the following month. The interest rate at December 31, 2018 was 5.84% .  All interest will be calculated based upon a year of 360 days for actual days elapsed. All interest will accrue from the Closing Date and will be payable monthly in arrears. Upon the occurrence and during the continuation of an Event of Default, all interest will be increased by 2% above the per annum rate otherwise applicable thereto. The Term Loans carry a prepayment penalty with respect to the prepayment of any portion of either Term Loan equal to 3% , 2% , and 1% of the amount prepaid in the first, second, and third years, respectively, of the credit agreement .  This credit agreement contains covenants related to various matters including certain financial covenants, prohibitions on further borrowings and security interests, merger or consolidation, acquisitions, guarantees, sales of assets other than in the normal course of business, leasing, and payment of dividends. The lender has a security interest in all assets and a mortgage encumbering certain real property.  Subsequent to year end, on March 7, 2019, the Company entered into the First Amendment to the Credit and Security Agreement in which the quarterly debt service coverage ratio mea surement requirements for 2019 were amended.  Other debt  Subordinated promissory notes  In December 2013, the Company completed a private offering in which the Company sold an aggregate of $500,000 in subordinated promissory notes and issued warrants to purchase 100,000 shares of common stock. $50,000 of the notes were repaid in 2016. In 2017, the Company paid one of the subordinated notes in the principal amount of $100,000 . The remaining five notes, totaling an aggregate principal amount of $350,000 , including $100,000 each with the two largest beneficial shareholders of the Company, were repaid in 2018. The Company carried $350,000 as restricted cash at December 31, 2017 for this purpose. A discount on the notes related to the attached warrants was being recognized as non-cash interest expense over the term of the notes. The Company recorded $0 and $17,989 of non-cash interest expense for the years ended December 31, 2018 and 2017.  No warrants were exercised in 2018 or 2017 and unexercised warrants expired on December 31, 2018.  Future maturities of term debt  Future maturities of term debt for the years ending December 31 are as follows:      2019 2020 2021 2022 2023 Thereafter Total  Term notes 457,143 3,623,809 — — — — 4,080,952

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
Income Taxes	8. Income Taxes  The income tax provision consists of the following:      Year Ended  December 31,  2018 2017  Current:  Federal $ — $ —  State 2,168 2,140  Total current income taxes 2,168 2,140  Deferred:  Federal — (3,100)  State — —  Total deferred income taxes — (3,100)  Total income tax provision (benefit) $ 2,168 $ (960)  The components of deferred income taxes are as follows:      Year Ended  December 31,  2018 2017  Deferred tax assets:   Net operating loss carryforwards $ 3,144,600 $ 2,936,800  Federal and state tax credit carryforwards 525,000 517,700  Accruals and reserves 104,400 81,500  Stock based compensation 68,300 64,300  Patents and intangibles 12,000 22,000  Other long-term 45,300 21,400  Total long-term deferred tax assets 3,899,600 3,643,700   Deferred tax valuation allowance (3,374,800) (3,172,100)  Deferred tax assets, net of allowance 524,800 471,600   Property, plant and equipment (43,500) (45,300)  Prepaid expenses (478,200) (423,200)  Total deferred tax liabilities (521,700) (468,500)   Net deferred tax assets $ 3,100 $ 3,100  In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this assessment. As of December 31, 2018, the Company continues to maintain a valuation allowance against all of its domestic and foreign deferred tax assets, except for its AMT Credit carryforward, which is treated as a refundable attribute under the new tax law.  On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code that affect fiscal 2017 including, but not limited to, a reduction of the U.S. federal corporate tax rate from 35% to 21% starting January 1, 2018, changes to bonus depreciation starting late September 2017, and the elimination of the Alternative Minimum Tax starting in 2018. The primary provision of the Tax Act which impacted the Company’s 2017 income tax provision relate to the revaluation of the Company's deferred tax assets and liabilities.  In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for income tax effects of the Tax Act. The final amounts may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act. The Company has completed is assessment of the impact of the Tax Act in 2018, and no change was recorded from the originally presented balances.  For the year ended December 31, 2018, the Company has federal and state net operating loss carryforwards totaling $11,300,000 and $12,195,000 , respectively, which begin to expire in 2031. The Company also had federal and state tax credit carryovers of $306,000 and $277,000 , respectively. The federal and state credits begin to expire in 2027 and 2018, respectively.  The Company files a consolidated federal income tax return. The actual income tax provision differs from applying the Federal statutory income tax rate ( 21% in 2018 and 34% in 2017) to the pre-income tax loss from continuing operations as follows:      Year Ended  December 31,  2018 2017  Tax benefit computed at statutory rate $ (216,791) $ (461,347)  Increases (reductions) due to:  Change in valuation allowance 202,700 (640,800)  State income taxes, net of federal benefit 1,713 1,431  Permanent differences 9,669 13,636  Tax credits (federal and state) (7,326) (73,618)  Change in tax rates — 1,002,994  Differences on prior returns (federal and state) 12,203 156,744  Income tax provision (benefit) $ 2,168 $ (960) 

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2018
Employee Benefit Plans [Abstract]
Employee Benefit Plans	9. Employee Benefit Plans  The Company sponsors an Employee Savings and Investment Plan under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. Employees can contribute up to 90% of their eligible compensation to the maximum allowable by the IRS. The Company’s matching contributions are at the discretion of the Company. The Company’s matching contributions in 2018 and 2017 were $39,039 and $42,215 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies  Legal matters  In the ordinary course of its business, the Company is involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material impact on the Company’s financial position or results of operations.  Operating lease agreements  Lease expense under all operating leases was approximately $24,033 and $24,954 for the years ended December 31, 2018 and 2017, respectively. Future minimum lease payments for the years ending December 31 are as follows:     2019 $ 20,222  2020 $ 18,222  2021 $ 10,630  

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2018
Shareholders' Equity [Abstract]
Shareholders' Equity	11. Shareholders’ equity  Common stock  In 2018 and 2017, the Company issued 21,734 and 22,635 shares of the Company’s common stock from treasury, pursuant to the 2010 Equity Incentive Plan, with a fair value of $75,750 and $88,524 , respectively, for directors’ fees in lieu of cash payments.  No shares were issued as a result of the exercise of stock options or the exercise of warrants in 2018 or 2017.  No dividends were declared or paid in 2018 or 2017.  Warrants  No warrants were exercised in 2018 or 2017 and 70,000 warrants expired on December 31, 2018. There are no warrants outstanding as of December 31, 2018.  Stock options and Share-Based Incentive Plan  In March 2010, the Company's Board of Directors adopted the Micron Solutions, Inc. 2010 Equity Incentive Plan (the “Plan”). The Plan authorizes the issuance of an aggregate of 500,000 shares. The Plan provides the Company flexibility to award a mix of stock options, equity incentive grants, performance awards and other types of stock-based compensation to certain eligible employees, non-employee directors, or consultants and under which an aggregate of 500,000 shares have been reserved for such grants. The options granted have ten year contractual terms that vest annually between three to five -year terms.  At December 31, 2018, there were options to acquire an aggregate of 393,500 shares outstanding. At December 31, 2017, there were options to acquire an aggregate of 205,500 shares outstanding.  The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the common stock using historical periods consistent with the expected term of the options. The expected term of options granted under the Company’s equity incentive plan, all of which qualify as “plain vanilla,” is based on the average of the contractual term and the vesting period as permitted under SEC Staff Accounting Bulletin Nos. 107 and 110. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option.  During 2018, there were 195,000 new option grants . No options were granted in 2017. The assumptions used to measure the fair value of option grants in 2018 and 2017 were as follows:      Year Ended  December 31,  2018 2017  Expected option term 5.5 to 6.25 -  Expected volatility factor 16.96% to 26.87% -  Risk-free rate 2.36% to 2.94% -  Expected annual dividend yield - -  The following table sets forth the stock option transactions for the year ended December 31, 2018:      Weighted  Weighted average  Average remaining Aggregate  Number of Exercise contractual Intrinsic  options Price term (in years) Value  Outstanding at December 31, 2017 205,500 $ 6.04 6.07 $ 28,750  Granted 195,000 3.64  Forfeited (7,000) 3.81  Outstanding at December 31, 2018 393,500 $ 4.89 7.22 $ 960  Exercisable at December 31, 2018 182,164 $ 6.09 4.81 $ 960  Exercisable at December 31, 2017 114,583 $ 6.42 5.30 $ 20,551  For the years ended December 31, 2018 and 2017 , share-based compensation expense related to stock options and the non-cash issuance of common stock amounted to $56,168 and $48,129 , respectively, and is included in general and administrative expenses. As of December 31, 2018, $127,944 of unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the stock option plan. This cost is expected to be recognized over a weighted average period of 2.59 years. The weighted average grant date fair value of grants made in 2018 was $0.55 .  At December 31, 2018 there were 31,631 shares available for future grants under the Plan, after giving effect to shares which became available for reissuance due to expired or forfeited options.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events  Changes to Management  Mr. Salvatore Emma, Jr.’s employment with the Company terminated effective February 8, 2019. Mr. Emma most recently served as Chief Operating Officer of the Company. On February 28, 2019, the Company and Mr. Emma entered into an Agreement and Release effective March 7, 2019. Subject to the terms of the agreement, Mr. Emma shall be entitled to, as a severance benefit, $1,187.50 per week over 24 months or an aggregate of $123,500 . The agreement also included a general release of claims by Mr. Emma and certain confidentiality, non-competition and non-solicitations and innovations provisions. 

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation  The consolidated financial statements (the "financial statements") include the accounts of Micron Solutions, Inc. and its operating subsidiary, Micron Products, Inc. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Revenue Recognition	Revenue recognition  The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ ASU”) No. 2014-09, “Revenue from Contracts with Customers, Topic 606” (“Topic 606”) effective January 1, 2018 using the modified retrospective approach. Under the modified retrospective method, a cumulative effect of initially applying the new standard is recorded as an adjustment to the opening balance of retained earnings at the date of initial application. By electing to use this method, there is no restatement of the comparative periods presented. As permitted by Topic 606 transition guidance, the Company applied the new standard only to contracts that were not completed contracts at the date of initial application, and therefore, the Company only evaluated those contracts that were in-process and not completed before January 1, 2018.  Beginning January 1, 2018, the Company applied Topic 606 using the five step approach outlined in the guidance: (1) Identify contracts with the customer, (2) Identify the performance obligations in the contract, (3) Determine the transaction price, (4) Allocate the transaction price to the performance obligations in the contract, and (5) Recognize revenue when (or as) the entity satisfies the performance obligations.  The Company determined that customer purchase orders represent contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. Shipping and handling activities for which the Company is responsible are not a separate promised service but instead are activities to fulfill the entity’s promise to transfer goods and are recognized at the same time as the related performance obligation is satisfied.  The Company determines the transaction price as the amount of consideration it expects to receive in exchange for transferring promised goods or services to the customer. If a contract includes a variable amount, such as a rebate, then the Company estimates the transaction price using either the expected value or the most likely amount of consideration to be received, depending upon the specific facts and circumstances. The Company includes estimated variable consideration in the transaction price only to the extent it is probable that a significant reversal of revenue will not occur when the uncertainty is resolved. The Company updates its estimate of variable consideration at the end of each reporting period to reflect changes in facts and circumstances.  The Company recognizes revenue at the point in time when it transfers control of the promised goods or services to the customer, which typically occurs once the product has shipped or has been delivered to the customer. For certain customer warehousing agreements, delivery is deemed to have occurred when the customer pulls inventory out of the warehouse for use in their production. Additionally, for certain customers, delivery is deemed to have occurred when items are delivered to bill and hold locations at the Company’s facility.  The Company evaluated the nature of any guarantees or warranties related to its contracts with customers. The Company determined that any such warranty is an assurance-type warranty that only covers the products’ compliance with agreed-upon specifications and does not provide the customer with a service in addition to the assurance that the product complies with agreed-upon specifications.  Certain contracts contain prepayment terms that result in liabilities for customer deposits. Additionally, certain contracts provide for invoicing before all performance obligations have been fulfilled which results in deferred revenue. Customer deposits and advance invoicing are recorded as contract liabilities on the consolidated balance sheet.  The Company generally expenses sales commission when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.  The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected duration of one year or less.
Fair value of financial instruments	Fair value of financial instruments  The carrying amount reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the immediate or short-term nature of such instruments. The carrying value of debt approximates fair value since it provides for market terms and interest rates.
Concentration of credit risk	Concentration of credit risk  Financial instruments which potentially expose the Company to concentrations of credit risk consist primarily of accounts receivable and cash and cash equivalents. It is the Company’s policy to place its cash in high quality financial institutions. The Company does not believe significant credit risk exists above federally insured limits with respect to these institutions.  Accounts receivable are customer obligations due under normal trade terms. A large portion of the Company's products are sold to large diversified medical, military and law enforcement product manufacturers. The Company does not generally require collateral for its sales; however, the Company believes that its terms of sale provide adequate protection against credit risk.  During the year ended December 31, 2018 , the Company had net sales to three customers constituting 18% , 12% and 10% of total net sales. Accounts receivable from these three customers at December 31, 2018 was 19% , 7% and 7% , respectively, of the total accounts receivable balance at year end. During the year ended December 31, 2017 , the Company had net sales to two customers constituting 17% and 10% , respectively, of total net sales. Accounts receivable from these two customers at December 31, 2017 was 13% and 3% , respectively, of the total accounts receivable balance at year end.  During the years ended December 31, 2018 and 2017 approximately 75% of the Company’s net sales were to customers in the medical industry. The Company also had net sales to customers in the automotive, industrial, consumer products, and military and law enforcement industries.  The Company competes globally, with approximately 45% of its revenue derived from exports. While some risks exist in foreign markets, the Company’s customers have historically been based in stable regions. To reduce the risks associated with foreign shipments and currency exchange fluctuations, the title to most of the products are transferred to the customers when shipped and payment is required in U.S. Dollars. The Company also has agreements with certain foreign customers to hold inventory at customer locations where title transfers and revenue is recognized when the product is consumed by the customer. To further reduce risk, the Company sells to certain markets only with cash-in-advance or letter-of-credit terms. In addition, accounts receivable insurance is used where available and appropriate to further reduce risk in these markets. 
Cash and cash equivalents	Cash and cash equivalents  Cash and cash equivalents consist of cash on hand and on deposit in high quality financial institutions with maturities of three months or less at the time of purchase. The Company’s credit agreement provides for a daily sweep of cash balances against the balance of the Revolver (see Note 7).
Restricted cash	Restricted cash  Restricted cash represents cash obtained pursuant to the Company's credit agreement for the designated purpose of discharging the subordinated promissory notes, which occurred on January 2, 2018 (see Note 7).
Accounts receivable and allowance for doubtful accounts	 Accounts receivable and allowance for doubtful accounts  Accounts receivable represent amounts invoiced by the Company. Management maintains an allowance for doubtful accounts based on information obtained regarding individual accounts and historical experience. Amounts deemed uncollectible are written off against the allowance for doubtful accounts. The Company insures receivables for certain customers based upon several factors. Such factors include the customer’s payment terms, ordering patterns and volume requirements, the customer’s payment history, or general economic conditions of the region in which a customer is located.
Inventories	Inventories  The Company values its inventory at the lower of average cost, or net realizable value, and cost is determined using first in first out (FIFO) or average cost. The Company reviews its inventory for quantities in excess of production requirements, obsolescence and for compliance with internal quality specifications. A review of inventory on hand is made at least annually and obsolete inventory may be disposed of and/or recycled. Any adjustments to inventory would be equal to the difference between the cost of inventory and the estimated net market value based upon assumptions about future demand, market conditions and expected cost to distribute those products to market. The Company also has supply agreements with certain foreign customers to hold inventory at the customer’s warehouses. 
Property, plant and equipment	Property, plant and equipment  Property, plant and equipment are recorded at cost and include expenditures which substantially extend their useful lives. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs are charged to earnings as incurred. When equipment is retired or sold, the resulting gain or loss is reflected in earnings.
Assets held for sale	Assets held for sale  Property classified as held for sale is measured at the lower of its carrying value or fair value less cost to sell. Gains or losses are recognized for any subsequent changes to fair value less cost to sell; however, gains that may be recognized are limited by cumulative losses previously recognized. Property held for sale is not depreciated. 
Fair value heirarchy	Fair value hierarchy  The Company groups its assets and liabilities measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.  Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities. Valuations are obtained from readily available pricing sources.  Level 2 – Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using unobservable inputs to pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.  In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.  At December 31, 2018 and 2017, assets held for sale is the only item in the financial statements reflected at fair value. Assets held for sale are considered level 3. The fair value of assets held for sale was determined using the sales price per the amended purchase and sale agreement, less the estimated cost to sell (see Note 6).
Long-lived and intangible assets	Long-lived and intangible assets  The Company assesses the impairment of long-lived assets and intangible assets with finite lives annually or whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. Based upon the annual review, the Company did not record any impairment charges in 2018. The Company recorded impairment charges of $1,771 in 2017.  Intangible assets consist of the following:      Estimated December 31, 2018 December 31, 2017  Useful Life Accumulated Accumulated  (in years) Gross Amortization Net Gross Amortization Net  Patents and trademarks 10 $ 36,880 $ 12,134 $ 24,746 $ 22,911 $ 9,888 $ 13,023  Patents and trademarks pending — 2,143 — 2,143 13,786 — 13,786  Trade names 15 29,398 3,132 26,266 29,062 738 28,324  Total intangible assets $ 68,421 $ 15,266 $ 53,155 $ 65,759 $ 10,626 $ 55,133  Amortization expense related to intangible assets, excluding the 2017 impairment charge noted above, was $4,639 and $2,496 in 2018 and 2017 , respectively. Estimated future annual amortization expense for currently amortizing intangible assets is expected to approximate $4,000 through 2031.
Income taxes	Income taxes  The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates in effect for the year in which the differences are expected to reverse.  The Company follows the provisions of FASB ASC 740, “Accounting for Income Taxes”, which provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized. No interest and penalties related to uncertain tax positions were incurred during 2018 and 2017. The Company’s primary operations are located in the United States. Tax years ended December 31, 2015 or later remain subject to examination by the IRS and state taxing authorities.
Share-based compensation	Share-based compensation  Share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the share-based grant).
Earnings per share data	Earnings per share data  Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares.
Research and development	Research and development  Research and development expenses include costs directly attributable to conducting research and development programs primarily related to the development of a unique process to improve silver coating during the manufacturing processes, including the design and testing of specific process improvements for certain medical device components. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, and services provided by outside contractors. All costs associated with research and development programs are expensed as incurred.
Recently Issued Accounting Pronouncements	Recently issued accounting pronouncements  In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Based upon this review, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s consolidated financial statements.  In February 2016 the FASB issued ASU No. 2016-02, Leases, which requires a lessee to recognize lease liabilities for the lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and right-of-use assets, representing the lessee’s right to use, or control the use of, specified assets for the lease term. The ASU became effective on January 1, 2019. As of the date of this report, the Company is the lessee of office equipment in a single operating lease and is the lessee of a parking lot. The Company is not a lessor in any arrangements. The Company does not expect any material impact on reporting or on the results of operations. 
Reclassification of prior period balances	Reclassification of prior period balances  Amounts in prior year financial statements are reclassified when necessary to conform to the current year presentation.

Accounting Policies (Tables)

Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule Of Intangible Assets	   Estimated December 31, 2018 December 31, 2017  Useful Life Accumulated Accumulated  (in years) Gross Amortization Net Gross Amortization Net  Patents and trademarks 10 $ 36,880 $ 12,134 $ 24,746 $ 22,911 $ 9,888 $ 13,023  Patents and trademarks pending — 2,143 — 2,143 13,786 — 13,786  Trade names 15 29,398 3,132 26,266 29,062 738 28,324  Total intangible assets $ 68,421 $ 15,266 $ 53,155 $ 65,759 $ 10,626 $ 55,133 

Change in Accounting Principle

Change in Accounting Principle (Tables)	12 Months Ended
	Dec. 31, 2018
Change in Accounting Principle [Abstract]
Affected Lines From Legacy GAAP Treatment on Statement of Operations/Balance Sheets	     Year Ended  December 31,  2018 2018  As presented Legacy GAAP  Net sales $ 19,564,981 $ 19,208,155  Cost of sales 17,241,289 16,979,892  Gross profit 2,323,692 2,228,263   Net loss from operations (757,580) (853,009)  Net loss before income tax provision (benefit) (1,096,139) (1,191,568)  Net loss $ (1,098,307) $ (1,193,736)  Earnings (loss) per share - basic and diluted $ (0.39) $ (0.42)  Weighted average common shares outstanding - basic and diluted 2,850,397 2,850,397   The table below compares the affected lines on the consolidated balance sheets as presented to legacy GAAP treatment.      December 31, December 31,  2018 2018  As presented Legacy GAAP  Assets  Current assets:  Prepaid expenses and other current assets $ 389,390 $ 488,817  Total current assets 7,090,718 7,190,145  Other assets 5,140 167,110  Total assets $ 12,280,786 $ 12,542,183  Liabilities and Shareholders’ Equity  Current liabilities:  Contract liabilities, current portion $ 560,802 $ 697,733  Total current liabilities 4,635,220 4,772,151  Long-term liabilities:  Contract liabilities, non-current portion — 219,895  Total long-term liabilities 3,557,458 3,777,353  Total liabilities 8,192,678 8,549,504  Shareholders’ equity :  Accumulated deficit (4,648,484) (4,743,913)  Total shareholders’ equity 4,088,108 3,992,679  Total liabilities and shareholders’ equity $ 12,280,786 $ 12,542,183 

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Inventories [Abstract]
Schedule Of Inventories	   December 31, December 31,  2018 2017  Raw materials $ 1,079,887 $ 1,100,187  Work-in-process 1,105,272 822,244  Finished goods 1,499,900 1,490,768  Total $ 3,685,059 $ 3,413,199 

Property, Plant and Equipment_2

Property, Plant and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net	   Asset Lives December 31, December 31,  (in years) 2018 2017  Machinery and equipment 3 to 15 $ 17,978,781 $ 17,498,586  Building and improvements 5 to 25 3,991,951 3,986,715  Vehicles 3 to 5 98,119 90,713  Furniture, fixtures, computers and software 3 to 5 1,440,071 1,542,027  Construction in progress 168,094 17,412  Total property, plant and equipment 23,677,016 23,135,453  Less: accumulated depreciation (18,545,243) (17,391,414)  Property, plant and equipment, net $ 5,131,773 $ 5,744,039 

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2018
Debt [Abstract]
Summary of Debt	   December 31, December 31,  2018 2017  Revolving line of credit $ 2,025,592 $ 1,879,047  Subordinated promissory notes $ — $ 350,000   Total term notes payable, net of issuance costs $ 3,946,878 $ 4,346,194  Less current portion, net 389,420 367,779  Term notes payable, non-current, net 3,557,458 3,978,415   Total short and long term debt, net $ 5,972,470 $ 6,575,241 
Future Maturities of Debt	   2019 2020 2021 2022 2023 Thereafter Total  Term notes 457,143 3,623,809 — — — — 4,080,952 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
Income Tax Provision	   Year Ended  December 31,  2018 2017  Current:  Federal $ — $ —  State 2,168 2,140  Total current income taxes 2,168 2,140  Deferred:  Federal — (3,100)  State — —  Total deferred income taxes — (3,100)  Total income tax provision (benefit) $ 2,168 $ (960) 
Deferred Income Taxes	   Year Ended  December 31,  2018 2017  Deferred tax assets:   Net operating loss carryforwards $ 3,144,600 $ 2,936,800  Federal and state tax credit carryforwards 525,000 517,700  Accruals and reserves 104,400 81,500  Stock based compensation 68,300 64,300  Patents and intangibles 12,000 22,000  Other long-term 45,300 21,400  Total long-term deferred tax assets 3,899,600 3,643,700   Deferred tax valuation allowance (3,374,800) (3,172,100)  Deferred tax assets, net of allowance 524,800 471,600   Property, plant and equipment (43,500) (45,300)  Prepaid expenses (478,200) (423,200)  Total deferred tax liabilities (521,700) (468,500)   Net deferred tax assets $ 3,100 $ 3,100 
Federal Income Taxes	   Year Ended  December 31,  2018 2017  Tax benefit computed at statutory rate $ (216,791) $ (461,347)  Increases (reductions) due to:  Change in valuation allowance 202,700 (640,800)  State income taxes, net of federal benefit 1,713 1,431  Permanent differences 9,669 13,636  Tax credits (federal and state) (7,326) (73,618)  Change in tax rates — 1,002,994  Differences on prior returns (federal and state) 12,203 156,744  Income tax provision (benefit) $ 2,168 $ (960) 

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Lease Payments	  2019 $ 20,222  2020 $ 18,222  2021 $ 10,630  

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Shareholders' Equity [Abstract]
Fair Value of Option Grants	   Year Ended  December 31,  2018 2017  Expected option term 5.5 to 6.25 -  Expected volatility factor 16.96% to 26.87% -  Risk-free rate 2.36% to 2.94% -  Expected annual dividend yield - - 
Stock Option Transactions	   Weighted  Weighted average  Average remaining Aggregate  Number of Exercise contractual Intrinsic  options Price term (in years) Value  Outstanding at December 31, 2017 205,500 $ 6.04 6.07 $ 28,750  Granted 195,000 3.64  Forfeited (7,000) 3.81  Outstanding at December 31, 2018 393,500 $ 4.89 7.22 $ 960  Exercisable at December 31, 2018 182,164 $ 6.09 4.81 $ 960  Exercisable at December 31, 2017 114,583 $ 6.42 5.30 $ 20,551 

Description of Business (Detail

Description of Business (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Description of Business [Abstract]
Percent of revenue derived from exports		45.00%
Cash and cash equivalents		$ 1,715	$ 606,988
Current borrowing capacity		$ 285,000
Repayment of revolver	$ 700,000

Accounting Policies (Narrative)

Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)customer	Dec. 31, 2017USD ($)customer
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of revenue derived from exports	45.00%
Impairment of intangibles | $	$ 0	$ 1,771
Amortization expense | $	4,639	$ 2,496
Estimated future amortization | $	$ 4,000
Sales Revenue, Net [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Number of customers, concentration of credit risk | customer	3	2
Sales Revenue, Net [Member] | Customer 1 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Concentration of credit risk, percentage	18.00%	17.00%
Sales Revenue, Net [Member] | Customer 2 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Concentration of credit risk, percentage	12.00%	10.00%
Sales Revenue, Net [Member] | Customer 3 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Concentration of credit risk, percentage	10.00%
Sales Revenue, Net [Member] | Medical Industry Customers [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Concentration of credit risk, percentage	75.00%	75.00%
Accounts Receivable [Member] | Customer 1 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Concentration of credit risk, percentage	19.00%	13.00%
Accounts Receivable [Member] | Two Customers [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Number of customers, concentration of credit risk | customer		2
Accounts Receivable [Member] | Customer 2 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Concentration of credit risk, percentage	7.00%	3.00%
Accounts Receivable [Member] | Customer 3 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Concentration of credit risk, percentage	7.00%
Accounts Receivable [Member] | Three Customers [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Number of customers, concentration of credit risk | customer	3

Accounting Policies (Schedule O

Accounting Policies (Schedule Of Intangible Assets) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross	$ 68,421	$ 65,759
Accumulated Amortization	15,266	10,626
Net	$ 53,155	55,133
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in years)	10 years
Gross	$ 36,880	22,911
Accumulated Amortization	12,134	9,888
Net	24,746	13,023
Patents and Trademarks Pending [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	2,143	13,786
Net	$ 2,143	13,786
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in years)	15 years
Gross	$ 29,398	29,062
Accumulated Amortization	3,132	738
Net	$ 26,266	$ 28,324

Change in Accounting Principl_2

Change in Accounting Principle (Narrative) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit	$ (4,648,484)	$ (3,536,186)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Restatement Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit		(13,991)
Deferred revenue, current		(18,333)
Deferred costs		$ (32,324)

Change in Accounting Principl_3

Change in Accounting Principle (Affected Lines From Legacy GAAP Treatment on Statement of Operations) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net sales	$ 19,564,981	$ 20,102,662
Cost of sales	17,241,289	17,810,284
Gross profit	2,323,692	2,292,378
Net income (loss) from operations	(757,580)	(1,018,390)
Net loss before income tax provision (benefit)	(1,096,139)	(1,356,056)
Net loss	$ (1,098,307)	$ (1,355,096)
Earnings (loss) per share - basic and diluted	$ (0.39)	$ (0.48)
Weighted average common shares outstanding - basic and diluted	2,850,397	2,824,061
Legacy GAAP [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net sales	$ 19,208,155
Cost of sales	16,979,892
Gross profit	2,228,263
Net income (loss) from operations	(853,009)
Net loss before income tax provision (benefit)	(1,191,568)
Net loss	$ (1,193,736)
Earnings (loss) per share - basic and diluted	$ (0.42)
Weighted average common shares outstanding - basic and diluted	2,850,397

Change in Accounting Principl_4

Change in Accounting Principle (Affected Lines From Legacy GAAP Treatment on Balance Sheets) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Prepaid expenses and other current assets	$ 389,390	$ 460,954
Total current assets	7,090,718	7,426,389
Other assets	5,140	10,289
Total assets	12,280,786	13,924,600
Contract liabilities, current portion	560,802	426,457
Total current liabilities	4,635,220	4,877,697
Total long-term liabilities	3,557,458	3,978,415
Total liabilities	8,192,678	8,856,112
Accumulated deficit	(4,648,484)	(3,536,186)
Total shareholders’ equity	4,088,108	5,068,488	$ 6,286,931
Total liabilities and shareholders’ equity	12,280,786	$ 13,924,600
Legacy GAAP [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Prepaid expenses and other current assets	488,817
Total current assets	7,190,145
Other assets	167,110
Total assets	12,542,183
Contract liabilities, current portion	697,733
Total current liabilities	4,772,151
Contract liabilities, non-current potion	219,895
Total long-term liabilities	3,777,353
Total liabilities	8,549,504
Accumulated deficit	(4,743,913)
Total shareholders’ equity	3,992,679
Total liabilities and shareholders’ equity	$ 12,542,183

Inventories (Narrative) (Detail

Inventories (Narrative) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventories [Abstract]
Silver inventory	$ 461,272	$ 536,963

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventories [Abstract]
Raw materials	$ 1,079,887	$ 1,100,187
Work-in-process	1,105,272	822,244
Finished goods	1,499,900	1,490,768
Total	$ 3,685,059	$ 3,413,199

Property, Plant and Equipment_3

Property, Plant and Equipment, net (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, net [Abstract]
Depreciation expense	$ 1,499,398	$ 1,608,643

Property, Plant and Equipment_4

Property, Plant and Equipment, net (Property, Plant and Equipment, net) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment
Total property, plant and equipment	$ 23,677,016	$ 23,135,453
Less: accumulated depreciation	(18,545,243)	(17,391,414)
Property, plant and equipment, net	5,131,773	5,744,039
Machinery and Equipment [Member]
Property, Plant and Equipment
Total property, plant and equipment	17,978,781	17,498,586
Building and Improvements [Member]
Property, Plant and Equipment
Total property, plant and equipment	3,991,951	3,986,715
Vehicles [Member]
Property, Plant and Equipment
Total property, plant and equipment	98,119	90,713
Furniture, Fixtures, Computers and Software [Member]
Property, Plant and Equipment
Total property, plant and equipment	1,440,071	1,542,027
Construction in Progress [Member]
Property, Plant and Equipment
Total property, plant and equipment	$ 168,094	$ 17,412
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment
Asset Lives (in years)	15 years
Maximum [Member] | Building and Improvements [Member]
Property, Plant and Equipment
Asset Lives (in years)	25 years
Maximum [Member] | Vehicles [Member]
Property, Plant and Equipment
Asset Lives (in years)	5 years
Maximum [Member] | Furniture, Fixtures, Computers and Software [Member]
Property, Plant and Equipment
Asset Lives (in years)	5 years
Minimum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment
Asset Lives (in years)	3 years
Minimum [Member] | Building and Improvements [Member]
Property, Plant and Equipment
Asset Lives (in years)	5 years
Minimum [Member] | Vehicles [Member]
Property, Plant and Equipment
Asset Lives (in years)	3 years
Minimum [Member] | Furniture, Fixtures, Computers and Software [Member]
Property, Plant and Equipment
Asset Lives (in years)	3 years

Assets Held For Sale (Details)

Assets Held For Sale (Details)	1 Months Ended
	Dec. 31, 2015ft²item	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Discontinued Operations [Line Items]
Assets held for sale, net | $		$ 0	$ 688,750
Fitchburg, Massachusetts [Member]
Discontinued Operations [Line Items]
Number of unoccupied buildings with letter of intent to sale | item	2
Area of building | ft²	52,000

Debt (Bank Debt Narrative) (Det

Debt (Bank Debt Narrative) (Details)	Dec. 29, 2017USD ($)item	Dec. 31, 2018USD ($)
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Revolver, interest rate at end of period		5.59%
Amount available under line of credit facility		$ 284,968
Revolving Credit Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Spread on variable rate		0.50%
Revolving Credit Facility [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Spread on variable rate		3.25%
Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 9,500,000
Debt maturity period		3 years
Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Expiration Date		Dec. 29, 2020
Quarterly unused facility fee, percent		0.25%
Maximum borrowing capacity	5,000,000
Agreement - Equipment Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	2,500,000
Monthly principal payments	$ 29,762
Debt instrument, maturity date		Dec. 29, 2020
Number of months, amortization schedule | item	84
Debt instrument, balloon payment	$ 1,458,333
Agreement - Real Estate Loan [Member]
Debt Instrument [Line Items]
Monthly principal payments	$ 8,333
Debt instrument, maturity date		Dec. 29, 2020
Number of months, amortization schedule | item	240
Debt instrument, balloon payment	$ 1,708,333
Agreement - Term Loans [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 2,000,000
Percent of increase in event of default	2.00%
Percent of prepayment penalty, year one	3.00%
Percent of prepayment penalty, year two	2.00%
Percent of prepayment penalty, year three	1.00%
Agreement - Term Loans [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Interest rate		5.84%
Spread on variable rate	0.75%
Agreement - Term Loans [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Spread on variable rate		3.50%

Debt (Other Debt Narrative) (De

Debt (Other Debt Narrative) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)itemshares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)	Dec. 29, 2017USD ($)	Dec. 31, 2013USD ($)shares
Debt Instruments [Line Items]
Payment on subordinated debt	$ 350,000	$ 100,000	$ 50,000
Number of notes remaining | item	5
Warrants to purchase outstanding | shares	0				100,000
Warrants exercised | shares	0	0
Non-cash interest expense	$ 0	$ 17,989
Restricted cash	0	$ 350,000
Two Largest Beneficial Shareholders [Member]
Debt Instruments [Line Items]
Payment on subordinated debt	$ 100,000
Warrants [Member]
Debt Instruments [Line Items]
Warrants exercised | shares	0	0
Agreement [Member]
Debt Instruments [Line Items]
Debt instrument, face amount				$ 9,500,000
Subordinated Debt [Member]
Debt Instruments [Line Items]
Debt instrument, face amount					$ 500,000

Debt (Summary of Debt) (Details

Debt (Summary of Debt) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Revolving line of credit	$ 2,025,592	$ 1,879,047
Subordinated promissory notes		350,000
Total short and long term debt, net	5,972,470	6,575,241
Term Notes Payable [Member]
Debt Instrument [Line Items]
Total term notes payable, net of issuance costs	3,946,878	4,346,194
Less current portion, net	389,420	367,779
Term notes payable, non-current, net	$ 3,557,458	$ 3,978,415

Debt (Future Minimum of Debt) (

Debt (Future Minimum of Debt) (Details) - Term Notes [Member]	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
2019	$ 457,143
2020	3,623,809
Total term notes payable, net of issuance costs	$ 4,080,952

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Abstract]
Net operating loss carryforwards	$ 11,300,000	$ 12,195,000
Tax credit carryforwards	$ 306,000	$ 277,000
Federal statutory income tax rate	21.00%	34.00%
Reduction to net deferred tax asset		$ 1,002,994

Income Taxes (Income Tax Provis

Income Taxes (Income Tax Provision) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Current:
State	$ 2,168	$ 2,140
Total current income taxes	2,168	2,140
Deferred:
Federal		(3,100)
Total deferred income taxes		(3,100)
Income tax benefit	$ 2,168	$ (960)

Income Taxes (Deferred Income T

Income Taxes (Deferred Income Taxes) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred income taxes:
Net operating loss carryforwards	$ 3,144,600	$ 2,936,800
Federal and state tax credit carryforward	525,000	517,700
Accruals and reserves	104,400	81,500
Stock based compensation	68,300	64,300
Patents and intangibles	12,000	22,000
Other long-term	45,300	21,400
Total long-term deferred tax assets	3,899,600	3,643,700
Deferred tax valuation allowance	(3,374,800)	(3,172,100)
Deferred tax assets, net of allowance	524,800	471,600
Property, plant and equipment	(43,500)	(45,300)
Prepaid expenses	(478,200)	(423,200)
Total deferred tax liabilities	(521,700)	(468,500)
Net deferred tax assets	$ 3,100	$ 3,100

Income Taxes (Federal Income Ta

Income Taxes (Federal Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Abstract]
Tax benefit computed at statutory rate	$ (216,791)	$ (461,347)
Change in valuation allowance	202,700	(640,800)
State income taxes, net of federal benefit	1,713	1,431
Permanent differences	9,669	13,636
Tax credits (federal and state)	(7,326)	(73,618)
Change in tax rates		1,002,994
Differences on prior returns (federal and state)	12,203	156,744
Income tax benefit	$ 2,168	$ (960)

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Benefit Plans [Abstract]
Maximum annual contribution per employee, percent of eligible compensation	90.00%
Matching 401K contribution	$ 39,039	$ 42,215

Commitments and Contingencies_2

Commitments and Contingencies (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies [Abstract]
Operating lease expense	$ 24,033	$ 24,954

Commitments and Contingencies_3

Commitments and Contingencies (Schedule of Future Minimum Lease Payments) (Details)	Dec. 31, 2018USD ($)
Commitments and Contingencies [Abstract]
2019	$ 20,222
2020	18,222
2021	$ 10,630

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock from treasury, shares	0	0
Issuance of common stock from treasury	$ 75,750	$ 88,524
Dividends declared or paid	$ 0	$ 0
Warrants unexercised	0		100,000
Number of warrants expired	70,000
Options outstanding	393,500	205,500
Number of options, granted in period	195,000	195,000
Unrecognized stock based compensation expense	$ 127,944
Unrecognized stock based compensation expense, recognition period	2 years 7 months 2 days
Weighted average grant date fair value	$ 0.55
Stock Options And Non-Cash Issuance Of Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 56,168	$ 48,129
The 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock from treasury, shares	21,734	22,635
Issuance of common stock from treasury	$ 75,750	$ 88,524
Shares authorized for issuance	500,000
The 2010 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual Term	10 years
Vesting period	5 years
The 2010 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Stock options and Share-Based Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants	31,631
Number of options, granted in period		0
Treasury Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock from treasury, shares	21,734	22,635
Issuance of common stock from treasury	$ 59,308	$ 61,766
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock from treasury, shares	0	0

Shareholders' Equity (Fair Valu

Shareholders' Equity (Fair Value of Option Grants) (Details)	12 Months Ended
	Dec. 31, 2018
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term, years	5 years 6 months
Expected volatility factor	16.96%
Risk-free rate	2.36%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term, years	6 years 3 months
Expected volatility factor	26.87%
Risk-free rate	2.94%

Shareholders' Equity (Stock Opt

Shareholders' Equity (Stock Option Transactions) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Shareholders' Equity [Abstract]
Number of options, outstanding, beginning balance	205,500
Number of options, Granted	195,000	195,000
Number of options, Forfeited	(7,000)
Number of options, outstanding, ending balance	393,500	205,500
Number of options, exercisable	182,164	114,583
Weighted Average Exercise Price, Outstanding, beginning of period	$ 6.04
Weighted Average Exercise Price, Granted	3.64
Weighted Average Exercise Price, Forfeited	3.81
Weighted Average Exercise Price, Outstanding, ending of period	4.89	$ 6.04
Weighted Average Exercise Price, Exercisable	$ 6.09	$ 6.42
Weighted average remaining contractual term (in years), Outstanding	7 years 2 months 19 days	6 years 26 days
Weighted average remaining contractual term (in years), Exercisable	4 years 9 months 22 days	5 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding	$ 960	$ 28,750
Aggregate Intrinsic Value, Exercisable	$ 960	$ 20,551

Subsequent Events (Details)

Subsequent Events (Details)	Mar. 07, 2019USD ($)
Subsequent Event [Member] | Chief Operating Officer [Member]
Subsequent Event [Line Items]
Severance Costs	$ 123,500